Document:

EX-10.35

 Exhibit 10.35 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

This document is an English translation of a document prepared in German. In preparing this document, an attempt has been made to translate as literally as
possible without jeopardizing the overall continuity of the text. Inevitably, however, differences may occur in translation and if they do, the German text will govern by law. 

In this translation, German legal concepts are expressed in English terms and not in their original German terms. The concepts concerned may not be
identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. 
  

 
 Loan agreement 

dated 18.07.2018 
 for a
DM SME loan of 
 EUR 9,450,000.00 

Between 
 JPT Peptide Technologies GmbH 

Volmerstraße 54 
 12489 Berlin 

(“Borrower”) 
 and 

Deutsche Bank AG 
 Business in Germany 

Ludwigsstraße 8-10 

55116 Mainz 
 (“Bank”) 

the following agreement (“Loan Agreement”) has been concluded for the granting of a repayment loan (“Loan”) on the basis of
the Bank’s General Business Terms and Conditions: 
 [Copy for the Bank / Copy for the client] 

  

 1. DEFINITIONS 

The following terms have the following meanings in the contractual text: 

“Payment date” is 15.12.2018 EUR 1,600,000.00; on 15.05.2019 EUR 3,000,000.00; on 15.10.2019 EUR 3,000,000.00 and on 15.01.2020 EUR
1,850,000.00. 
 “Banking day” is any day (with the exception of Saturday and Sunday) on which commercial banks are open to the
public for business in Frankfurt/Main. 
 “Final due date” is 30.09.2028. 

“Financial liabilities” are all liabilities from (i) borrowings (ii) issued letters of credit and accepted or issued bills
(iii) the issue of bonds, “commercial papers” or other debentures, (iv) lease contracts that under the applicable edicts of the Federal Ministry of Finance or the respective tax or balance sheet provisions of the Jurisdictions
regulating the lease contract, are to be treated as finance [operating] leases, (v) the sale of receivables where recourse against a member of the company group of the Borrower cannot be ruled out (recourse factoring), (vi) trade accounts
payable when a payment schedule is granted that lies outside common industry practices, (vii) derivatives, whereby when calculating the value of a derivative transaction only the
“mark-to-market value” is taken into consideration, (viii) recourse liability in respect of third party sureties, guarantees, bonds, letters of credit or
other financial instruments, where such are not included twice in the balance sheet concerned since the respective principle debt is already accounted for, (ix) other transactions when these have the economic effect of borrowings as defined in
paras. (i) to (viii), (x) a guarantee, surety or other co-liability for one of the liabilities cited in paras. (i) to (ix) liabilities, and (xi) pension provisions. 

2. LOAN  
 a) Loan amount 

The Bank is granting the Borrower a redeemable loan of EUR 9,450,000.00 (in words: nine million four hundred and fifty thousand Euro)
(“loan amount”). 
 b) Purpose 
 The
loan serves the co-financing of the company property to be built in Berlin-Adlershof. The Bank is entitled but not obliged, in respect of the Borrower, to monitor compliance with the loan purpose. 

3. PAYMENT 
 a) Payment date 

The Bank shall pay the Borrower the loan amount on the payment dates at the payout ratio of 100% provided that at that time the payment requirements specified
below in Clause 6 of this Loan Agreement have been satisfied. 

  
 - 2 - 

 b) Non-acceptance indemnity 

If the payment cannot, or cannot fully, be paid out on the payment date for reasons attributable to the Borrower, the Borrower is obliged to compensate the
Bank for any losses caused through non-acceptance or late acceptance. 
 4. REDEMPTION/REPAYMENT  

a) Standard repayment 
 The loan is to repayable in 32
equal consecutive instalments of EUR 286,364.00 and a final, differing instalment of EUR 286,352.00. The instalments are payable quarterly in arrears on 31.03., 30.06., 30.09. and 31.12. of each year; the first instalment is due on.09.2020, the
final instalment is repayable on the final due date. 
 Any loan amounts outstanding on the final due date shall be paid on the final due date. 

b) Adjustment of payment schedules 
 If one of the dates
cited in the above paragraphs is not a banking day, repayment shall take place on the next banking day, unless as a result the repayment would only take place in a new calendar month or the following banking day lies after the final due date; in
such an event repayment shall take place on the next earlier banking day. 
 5. INTEREST / COMMISSIONS 

a) Debit authorisation 
 The Borrower herewith instructs
the Bank to debit any due repayment amounts, interest, costs, payments, expenses and commissions against the Borrower’s account [***] provided no different agreement has been reached in any individual instance. 

b) Interest 
 The interest rate is fixed for the entire
term and amounts to 2.08% p.a. The interest is charged on the basis of 30/360 days. It becomes due at the end of each Quarter. 
 6. PAYMENT
REQUIREMENTS 
 The Borrower can draw down the loan as soon as all the following, agreed payment requirements have been satisfied and one or more of the
same do not subsequently lapse: 
 a) The Bank has all the following documents and evidence in satisfactory form and the corresponding evidence has
not subsequently proved to be incorrect: 
  

	 	•	 	 All the details required under the Federal Money Laundering Act (GwG) regarding the financial beneficiaries and
the agreement on the loan purpose within the framework of this agreement 

  

	 	•	 	 All the agreed securities have been validly constituted 

 

	 	•	 	 Submission of the signed annual accounts 31.12.2017 

  
 - 3 - 

	b)	 The Borrower is not in default towards the Bank in the satisfaction of a due claim;

  

	c)	 No important reason exists that would entitle the Bank to extraordinary termination of this Loan
Agreement or that may entitled it to such termination after an additional deadline and/ or warning. 

 The Bank may make payment without
all payment requirements having to be satisfied. The obligation of the Borrower to satisfy the payment requirements remains thereby unaffected unless the Bank has waived satisfaction of specific payment requirements in writing. 

7. SECURITIES 
  

	a)	 The creation of the following securities has been agreed: 

 

	 	•	 	 First-priority land charges of EUR 9,450,000.00 on Betriebsimmobil (“commercial property”)
Berlin-Adlershof; Treptow Land Register, Page 31392N 

  

	 	•	 	 Indefinite directly enforceable guarantee by BioNTech AG in the amount of EUR 9,450,000.00 

 

	 	•	 	 Loan maintenance and subordination agreement in respect of a still-to-be provided shareholder group loan of EUR 9,450,000.00. Please send us the loan agreement when available. 

Individual details, in particular concerning the security purpose, are or shall be regulated in the security agreements. 

Where not agreed otherwise, the securities are to be created having first priority and free of third party rights of
set-off, retention or other rights. 
  

	b)	 On the basis of its lien under Nr. 14 AGB the Bank is in particular serviced by all current and future
deposits in account Nr. [***] and time deposits deposited against this account with the Bank including interest as security for all existing, future and conditional claims against the Borrower from and in connection with this Loan Agreement.
Disposal of these is only possible with the express permission of the Bank. 

 8. GENERAL OBLIGATIONS  

The Borrower furthermore and until satisfaction of all claims of the Bank from draw-downs under this Loan Agreement assumes the following obligations: 

a) Information obligations 
 Information on financial
situation: The Borrower shall continually update the Bank regarding its financial situation and, where applicable, the financial situation of its group of companies. 

In this regard it shall provide the Bank in particular with its latest annual accounts plus notes and management report and a consolidated annual account
(consolidated balance sheet, consolidated P&L account and consolidated notes) together with a consolidated management report on the Group including the respective auditor’s reports immediately on completion, at the latest however within 9
months of conclusion of the respective financial year, in the original and at least having the scope legally required. Where the annual accounts do not have to be certified, the Bank shall be given copies bearing the legally-binding signatures of
all directors or all liable partners. 

  
 - 4 - 

 Moreover the Borrower shall provide the Bank with quarterly business evaluations, liquidity figures, balance
sheet status and target-performance analyses. 
 Moreover the Borrower shall provide the Bank with its annual planning per 31st January of each calendar year. 
 Further documents providing an up-to-date view of the financial situation shall be submitted by the Borrower on request. 
 Information under
the Federal Money Laundering Act: The Borrower shall satisfy all its obligations under the Federal Money Laundering Act and in particular report any changes in the financial beneficiaries occurring over the term of this Loan Agreement
immediately and without request and provide the Bank on request with documentation and information for ascertaining and checking its details. 

Incorrect/incomplete information: The Borrower shall immediately notify the Bank should any information or documentation provided (also planning and
forecasts) show significant negative changes or deviations or should it transpire that the information or documentation supplied was incomplete or incorrect. 

b) Change in shareholder structure 
 The Parties are
agreed that the current shareholder structure constitutes an important basis for the willingness of the Bank to grant this loan and the authorisation of all draw-downs under the same. In the event of any change in the shareholder structure the
Parties shall reach a mutually-satisfactory agreement on the continuation of this Loan Agreement, where applicable subject to amended conditions, for example regarding interest, securities or other agreements before such a situation arises. 

c) Credit agreements with other credit institutions 
 The
Borrower shall inform the Bank of any new credit agreements that exceed the amount of EUR 500,000.00 or if there are significant changes to its current credit agreements with other credit institutions (for example increase, termination or collateral
requirements), where these are the subject of negotiations, where possible in advance, otherwise immediately thereafter. 
 9. EXTRAORDINARY RIGHT OF
TERMINATION 
 An important reason entitling the Bank to extraordinary termination of this Loan Agreement under Nr. 19 para. 3 AGB in particular
exists when: 
  

	a)	 The Borrower fails to satisfy the general obligations or other essential obligations agreed under
this Loan Agreement and fails to comply with the security agreements concluded in connection with this Loan Agreement or 

  
 - 5 - 

	b)	 A change takes place to the shareholder structure and the Parties do not promptly agree to the
continuation of any changed conditions, for example regarding interest accrual, securities or other agreements or 

  

	c)	 The Borrower fails to or cannot satisfy its financial liabilities towards third party credit
institutions on becoming due or third party credit institutions prematurely call in or could call in such financial liabilities on the basis of a reason for termination, where the financial liabilities concerned exceed a sum of EUR 100,000.00 (or
the equivalent value in other currencies). 

 10. MISCELLANEOUS 

a) Forward transactions 
 Where the Bank and Borrower, to
secure the interest or currency risk under this Loan Agreement, conclude or have already concluded forward transactions – which the Bank is not obliged to do – the continued existence of these forward transactions is not affected by any
termination of this Loan Agreement. 
 b) Information disclosure 

Where the Bank, for refinancing, risk hedging or capital relief, makes use of its right to transfer the credit risk or claims under this Loan Agreement or
otherwise dispose of the same, the Bank is entitled to pass on borrower-related information to authorised recipients that by force of Law, contract or occupational or professional regulation are obliged to maintain confidentiality. Authorised
information recipients are members of the European Central Bank system, credit institutions, development banks, financial service providers, finance companies, insurance companies, pension funds, capital management companies, special purpose
vehicles founded for assuming credit risks and persons that for technical or legal reasons are to be involved in the transfer (for example auditors and rating agencies). 

c) Written form 
 Changes to this Loan Agreement must be
made in writing. 
 d) Acceptance deadline/ Validity of agreement 

The Bank considers itself bound by the offer submitted with this Loan Agreement until 17.08.2018. 

This Loan Agreement takes effect on receipt of the agreement signed by all the parties within the aforesaid acceptance deadline. 

e) Severability clause 
 Should individual provisions of
this Loan Agreement be or become wholly or partly – for whatever reasons – void or invalid or unworkable, this shall not affect the other provisions of this Loan Agreement. 

This Loan Agreement is cited under the date given in the heading. 

  
 - 6 - 

 Declaration pursuant to the Federal Money Laundering Act: 

The Borrower guarantees the Bank by crossing or initialling that it is solely drawing down the funds granted under this Loan Agreement for its own account:

 x JPT Peptide Technologies GmbH 
  

			
	Deutsche Bank AG	  	
	Business in Germany	  	
		
	Mainz, 19.07.2018	  	[Signature]
	Place, date	  	[***]
		
	Mainz, 19.07.2018	  	[Signature]
	Place, date	  	[***]
	
	JPT Peptide Technologies GmbH
		
	Place, date	  	Legally-binding signature(s)

  
 - 7 -EX-10.36

 Exhibit 10.36 

INVESTMENT AGREEMENT 

relating to 
 an equity
investment by the BILL & MELINDA GATES FOUNDATION into BIONTECH SE 

Dated: 30 August 2019 
 by and
between 
  

	1.	 BioNTech SE, An der Goldgrube 12, 55131 Mainz (the Company) 

and 
  

	2.	 Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation organized and existing under the laws of Washington and having its principal place of business at 500 Fifth Avenue North, Seattle, Washington 98109, United States (the
Foundation or Investor) 

 - the Company together with the Foundation being referred to as 

the Parties and each of them a Party - 

 TABLE OF CONTENTS 

 

							
	 1.
	 	COMMITMENT TO SUBSCRIBE FOR FOUNDATION SHARES	  	 	5	 
			
	2.	 	 CONTRIBUTION TO CAPITAL RESERVES
	  	 	7	 
			
	3.	 	 OBLIGATIONS OF COMPANY
	  	 	7	 
			
	4.	 	 GUARANTEES AND RELATED PROVISIONS
	  	 	7	 
			
	5.	 	 WITHDRAWAL RIGHT
	  	 	10	 
			
	6.	 	 SHAREHOLDERS’ AGREEMENT
	  	 	10	 
			
	7.	 	 FINAL PROVISIONS
	  	 	11	 
		
	SCHEDULE 1 CORPORATE ACTION IN RELATION TO WITHDRAWAL RIGHT	  	 	13	 
		
	SCHEDULE 2 AMENDED SHA	  	 	14	 
		
	SCHEDULE 3 BUSINESS GUARANTEES	  	 	15	 
		
	SCHEDULE 4 WITHDRAWAL RIGHT	  	 	17	 
			
	 1.
	 	 CONDITION PRECEDENT FOR WITHDRAWAL RIGHT AND DEFINITIONS
	  	 	17	 
			
	 2.
	 	 PUT-OPTION
	  	 	17	 
			
	 3.
	 	 SALE TO THIRD PARTY
	  	 	18	 
			
	 4.
	 	 REPORT ON HOLDINGS FOR COMPANY’S ACCOUNTING PURPOSES
	  	 	19	 
			
	 5.
	 	 SPECIFIC OBLIGATIONS TO ENSURE THE WITHDRAWAL RIGHT
	  	 	19	 
			
	 6.
	 	 COSTS
	  	 	21	 
			
	 7.
	 	 NO EFFECT ON LETTER AGREEMENT
	  	 	21	 

  
 2 | 22 

 INDEX OF DEFINED TERMS

  

					
	 Actual Conversion Rate
	  	 	6	 
	 Additional Payment
	  	 	7	 
	 ADS
	  	 	17	 
	 Aggregate EUR Issuance Price
	  	 	5	 
	 Aggregate Minimum Purchase Price
	  	 	21	 
	 Aggregate USD Issuance Price
	  	 	20	 
	 Amended SHA
	  	 	5	 
	 Annexes
	  	 	5	 
	 Articles
	  	 	4	 
	 Available Liquidity
	  	 	17	 
	 Best Knowledge
	  	 	8	 
	 BioNTech
	  	 	4	 
	 Breach of Guarantee
	  	 	8	 
	 Build-up Obligation
	  	 	20	 
	 Business Day
	  	 	5	 
	 Business Guarantees
	  	 	8	 
	 Capital Increase
	  	 	5	 
	 Capital Increase Account
	  	 	5	 
	 Clauses
	  	 	5	 
	 Closing Date
	  	 	5	 
	 Company
	  	 	1	 
	 Compensating Capital Increase
	  	 	9	 
	 Current Foundation Shares
	  	 	17	 
	 Default Period
	  	 	20	 
	 Distribution
	  	 	20	 
	 EUR Issuance Price
	  	 	6	 
	 Exercise Date
	  	 	17	 
	 Exhibits
	  	 	5	 
	 FMV Purchase Price
	  	 	17	 
	 Foundation
	  	 	1	 
	 Foundation ADS
	  	 	19	 
	 Foundation Shares
	  	 	4	 
	 Free Capital Reserves Accounting Treatment
	  	 	7	 
	 Group
	  	 	4	 
	 Group Company
	  	 	4	 

					
	 Guarantees
	  	 	8	 
	 Investment
	  	 	4	 
	 Investment Agreement
	  	 	5	 
	 Knowledge
	  	 	8	 
	 Letter Agreement
	  	 	4	 
	 Letter Effective Date
	  	 	5	 
	 Minimum Purchase Price
	  	 	17	 
	 Money Laundering Laws
	  	 	16	 
	 OFAC
	  	 	16	 
	 Option Readiness Notice
	  	 	18	 
	 Parties
	  	 	1	 
	 Party
	  	 	1	 
	 Purchase Price Put Option
	  	 	18	 
	 Put-Option
	  	 	17	 
	 Put-Option Exercise
	  	 	17	 
	 Put-Option Shares
	  	 	18	 
	 Registration
	  	 	7	 
	 Sale Request
	  	 	18	 
	 Schedules
	  	 	5	 
	 Share
	  	 	4	 
	 Share Capital
	  	 	4	 
	 Shareholder
	  	 	4	 
	 Shareholders
	  	 	4	 
	 Shareholders’ Agreement
	  	 	4	 
	 Shortfall Amount
	  	 	20	 
	 Shortfall Amount Note
	  	 	20	 
	 Stock-Split
	  	 	4	 
	 Subscription Form
	  	 	6	 
	 Taxes
	  	 	16	 
	 Title Guarantees
	  	 	8	 
	 Unadjusted Aggregate EUR Issuance Price
	  	 	6	 
	 Unrestricted Reserves
	  	 	17	 
	 USD Issuance Price
	  	 	4	 
	 Withdrawal Right
	  	 	17	 

 
 

  
 LIST
OF SCHEDULES AND EXHIBITS 
  

			
	Schedule 1	  	Corporate action in relation to Withdrawal Right
		
	Schedule 2	  	Amended SHA
		
	Schedule 3	  	Business Guarantees
		
	Schedule 4	  	Withdrawal Right
	
	 Exhibit Business Guarantees (6)

	
	 Exhibit Business Guarantees (9)

  
 3 | 22 

 WHEREAS 
  

	(A)	 The Company is a European company under German law (Societas Europaea), registered with the commercial
register of the local court of Mainz under HRB 48720 and having its registered business address at An der Goldgrube 12, 55131 Mainz, Germany. 

  

	(B)	 The Company’s business is the research, development and manufacture of pharmaceuticals for individualized
immunotherapies (diagnosis and treatment) of cancer and other diseases which it conducts itself or via its subsidiaries (each of the Company and each such subsidiary a Group Company and the group formed by the Company and such
subsidiaries the Group) such as BioNTech RNA Pharmaceuticals GmbH (the latter and the Company collectively BioNTech). The Foundation is a charitable trust committed to accelerating the development of lifesaving and low-cost therapeutics, diagnostics, and prophylactics to reduce the burden of disease in developing countries in furtherance of its mission to help all people live healthy, productive lives. 

 

	(C)	 At present, the registered share capital (Grundkapital) of the Company (the Share Capital)
amounts to EUR 12,152,676 and is divided into 12,152,676 ordinary shares with an imputed nominal value (Stückaktien) of EUR 1.00 each (each existing or future share in the Company hereinafter being referred to as a
Share), but is expected to, prior to the Closing Date (as such term is defined below), increase by EUR 206,595,492 to EUR 218,748,168 by way of conversion of reserves (Kapitalerhöhung aus Gesellschaftsmitteln)
(the Stock-Split). The existing Shares are fully paid in. The existing Shares are registered shares (Namensaktien); any transfer of the existing Shares requires the Company’s approval (Vinkulierung), to be provided
by the company’s supervisory board as laid down in more detail in section 5 of the Company’s articles of association (the Articles). The existing Shares have been entered into a share register (Aktienregister) held by
the Company. The existing Shares are held by the existing Shareholders as listed in the share register dated 16 August 2019 (the Shareholders and each a Shareholder). Certain of the Shareholders who had a
specific need for that have been issued share certificates. Following the Stock-Split, the Company is expected to have an authorized capital (Genehmigtes Kapital) of EUR 109,374,084. 

 

	(D)	 The Shareholders are parties to a shareholders agreement originally entered into on 29 December 2017 and
most recently amended with effect as from 27 August 2019 (the Shareholders’ Agreement). 

  

	(E)	 On or about the date hereof, BioNTech and the Foundation have entered into an agreement pursuant to which the
Foundation is to make an equity investment into the Company in consideration of the Company incurring the Global Access Commitments as defined in that agreement (the Letter Agreement, with such investment pursuant to the Letter
Agreement being referred to as the Investment). 

  

	(F)	 Based on the valuation of the Company on which the Parties have agreed, the Foundation wishes to subscribe for
3,038,674 Shares at an issuance price of USD 18.10 per Share (the USD Issuance Price, with the Shares so to be subscribed for by the Foundation or actually issued to it, as the context may suggest, being referred to as the
Foundation Shares and the process by which the Foundation Shares are issued to the Foundation (potentially alongside other Shares to other investors) being referred to as

  
 4 | 22 

	 	
the Capital Increase). The Company will use its authorized capital to issue the Foundation Shares. 

 

	(G)	 This investment agreement including the Recitals, all clauses (the Clauses), all annexes, (the
Annexes) and all schedules and exhibits (the Schedules and Exhibits) (collectively the Investment Agreement), is to set out the commitments of the Parties immediately in relation to the
Investment and the prerequisites to be satisfied for the Investment to occur, including the entry into force of an amendment to the Shareholders’ Agreement such that same will take the form of the Amended SHA (as such term is defined below),
for the purpose of establishing certain rights and preferences for the Foundation in its capacity as a Shareholder. 

 NOW THEREFORE in
consideration of the above, the Parties agree as follows: 
  

	1.	 Commitment to subscribe for Foundation Shares 

 

	1.1	 Subject to the Conditions having been satisfied and the Subscription Form received by the Foundation (the day
on which the Conditions so have been satisfied and the Subscription Form received being the Closing Date), the Foundation shall promptly and in no event later than within seven Business Days (a Business Day means any day
(other than a day which is a Saturday, Sunday or legal or bank holiday in Mainz, Germany) after the Closing Date, subscribe (übernehmen) for the Foundation Shares by way of executing and delivering the original of the Subscription
Form pursuant to Clause 1.2(f)) (via email in advance) and transfer to the Company the EUR Issuance Price (as defined in Clause 1.3) multiplied by the number of the Foundation Shares (this product, subject to Clause 1.4, being referred to as the
Aggregate EUR Issuance Price), which payment shall be made by bank remittance in Euro net of costs to the following no-debit-balance account of the Company (the Capital Increase
Account ): 

  

			
	Account holder	  	[***]
		 
	IBAN	  	[***]
		 
	SWIFT	  	[***]
		 
	Reference	  	Gates Foundation Capital Increase

  

	1.2	 Conditions shall mean the following conditions: 

 

	 	(a)	 The Letter Agreement has been entered into and all conditions to same taking effect have been satisfied or
validly waived (the Letter Effective Date). 

  

	 	(b)	 The prerequisites for the management board of the Company to be permitted to admit the Foundation to
subscription of the Foundation Shares are met. 

  

	 	(c)	 The corporate action specified in Schedule 1 (Corporate action in relation to Withdrawal
Right) has taken effect. 

  

	 	(d)	 The Stock-Split has taken effect. 

 

	 	(e)	 The Shareholders’ Agreement has been amended such that the Foundation Shares upon their issuance carry the
financial preferences set out to apply for them in the draft for an amended shareholders’ agreement attached hereto as Schedule 2 (Amended SHA) (the Amended SHA). 

  
 5 | 22 

	 	(f)	 After the satisfaction of the Conditions set out in paras. (b) through (e) and the Company having provided
reasonable evidence that such Conditions have been satisfied, the Company has submitted to the Foundation a draft subscription form (Zeichnungsschein) in relation to the Foundation Shares (i) which meets the prerequisites of Clause 1.3,
(ii) and conforms to the requirements of section 185 of the German Stock Corporation Act (Aktiengesetz, AktG) (the draft subscription form actually submitted and meeting such prerequisites being the Subscription Form).

  

	1.3	 The subscription form to be submitted pursuant to Clause 1.2(f) must 

 

	 	(a)	 name the Foundation as the subscriber, 

 

	 	(b)	 specify as the number of Shares to be subscribed the number of the Foundation Shares, 

 

	 	(c)	 specify as the issuance price per Share to be subscribed an amount in EUR equal to the USD Issuance Price
divided by the reference rate of the European Central Bank for United States Dollars expressed as the number of United States Dollars exchangeable for each one Euro for the last Business Day immediately preceding the date on which the Subscription
Form is submitted (or a lower amount in EUR), with the amount in EUR so specified being the EUR Issuance Price, 

  

	 	(d)	 specify as the date on which the subscription becomes invalid a date no later than two months after the date on
which the Subscription Form is submitted, and 

  

	 	(e)	 otherwise be in accordance with the German Public Companies Act (Aktiengesetz, AktG).

  

	1.4	 In the event that as of the time the Foundation is about to pay the Aggregate EUR Issuance Price as would
otherwise result from Clause 1.1 (the Unadjusted Aggregate EUR Issuance Price) the Unadjusted Aggregate EUR Issuance Price converted into United States Dollars on the basis of the conversion rate applied by the bank from which the
Foundation procures the Euro for the payment pursuant to Clause 1.1 (Actual Conversion Rate) is more than USD 55 million, the Foundation may elect to subscribe for that lower number of Shares (with such new number of
Shares for all purposes hereof henceforth being the Foundation Shares and the Aggregate EUR Issuance Price reducing accordingly) that the Aggregate EUR Issuance Price converted into United States Dollars on the basis of the Actual Conversion Rate
comes as close as possible to but does not exceed USD 55 million. 

  

	1.5	 This Investment Agreement shall terminate in the event that the Letter Agreement has been terminated before the
Conditions have been satisfied or waived. Further the Foundation may terminate this Investment Agreement by written notice to the Company in the event that any of the Conditions set out in Clauses 1.2(a) (to the extent the Company is responsible for
fulfilling such Condition) through 1.2(f) has not been satisfied after two months after the Letter Effective Date. 

  
 6 | 22 

	2.	 Contribution to capital reserves 

 

	2.1	 The Foundation and the Company agree that the Aggregate EUR Issuance Price, to the extent it exceeds the sum of
EUR 1.00 multiplied by the number of Foundation Shares (such excess the Additional Payment) shall be booked into the free capital reserves pursuant to section 272 paragraph 2 no. 4 of the German Commercial Code (Handelsgesetzbuch,
HGB) (the Free Capital Reserves Accounting Treatment). 

  

	2.2	 For the avoidance of doubt, the parties acknowledge that in the event the Free Capital Reserves Accounting
Treatment will be formally challenged by a court, the Company’s auditors or any other governmental or regulatory body, the Company shall promptly notify the Foundation and shall use reasonable best efforts to maintain the Free Capital Reserves
Accounting Treatment; provided that if despite using reasonable best efforts the Company on the advice of legal counsel or its auditors determines it is not permissible to maintain the Free Capital Reserves Accounting Treatment, the Company shall
book the Additional Payment as an amount attained in respect of the issuance of shares pursuant to section 272 paragraph 2 no. 1 of the German Commercial Code (Handelsgesetzbuch, HGB) or such other capital reserve as applies in the opinion of
the relevant party. 

  

	3.	 Obligations of Company 

 

	3.1	 Promptly upon receipt of the Subscription Form duly executed and the EUR Issuance Price times the number of
Foundation Shares, the Company shall without undue delay (unverzüglich), and in any event within five (5) Business Days from such receipt, apply for the registration of the implementation (Durchführung) of the Capital
Increase with the commercial register (such registration of the implementation of the Capital Increase, the Registration) and shall take all measures and make all declarations necessary or appropriate to cause the Registration to
occur. 

  

	3.2	 The Company shall not in any way transfer the monies received from the above account or utilize them until
Registration has occurred. 

  

	4.	 Guarantees and Related Provisions 

 

	4.1	 Title Guarantees 

The Company hereby represents and warrants to the Foundation regardless of fault or negligence by way of an independent guarantee
(selbständiges Garantieversprechen) (section 311 paragraph 1 of the German Civil Code (Bürgerliches Gesetzbuch)) that as of the date hereof and as of the Closing Date: 

 

	 	(a)	 The Company has been duly incorporated under German law and is validly existing as a Societas Europaea
(SE). 

  

	 	(b)	 The Shares held by each Shareholder are validly issued and fully paid in. There has been no direct or indirect
repayment (whether openly or concealed) of contributions to a Shareholder (Rückgewähr von Einlagen). No hidden contributions in kind (verdeckte Sacheinlagen) have been made. There exist no obligations to make further
contributions (keine Nachschusspflichten). 

  
 7 | 22 

	 	(c)	 The Foundation Shares will be free of encumbrances and any rights of third parties and are not subject to any
disposal restrictions, in each case subject to the Shareholders’ Agreement. 

  

	 	(d)	 The Company has unrestricted economic and legal authority and capacity to enter into this Investment Agreement
and to issue new shares, which has been duly authorized by all necessary corporate and/or legal action and is in compliance with the Shareholders’ Agreement and any other agreements between the Company and its shareholders.

  

	 	(e)	 Upon the Shares having been validly subscribed for by the Foundation, the Foundation having made its
contribution and the Registration having occurred, the Foundation will hold full legal and economic title to the Foundation Shares. 

  

	 	(f)	 This Investment Agreement and the Shareholders’ Agreement have been duly executed by or on behalf of the
Company and constitute their legal, valid and binding obligations enforceable under applicable law against the Company in accordance with its terms. 

(the Title Guarantees). 
  

	4.2	 Business Guarantees 

The Company hereby guarantees to the Foundation regardless of fault or negligence by way of an independent guarantee (selbständiges
Garantieversprechen) (section 311 paragraph 1 of the German Civil Code (Bürgerliches Gesetzbuch)) that the statements set forth in Schedule 3 (Business Guarantees) are true, accurate and complete as of the date
of this Agreement (the Business Guarantees, with the Business Guarantees and the Title Guarantees collectively referred to as the Guarantees). For these purposes, each of those such statements that are qualified as being
given to the Company’s Knowledge or Best Knowledge shall be deemed accurate unless where and to the extent any of Ugur Sahin, Sean Marett, Sierk Poetting and Özlem Türeci has actual knowledge or do not
actually know due to negligence (fahrlässige Unkenntnis) on the basis of the care of a prudent businessman (Sorgfalt eines ordentlichen Geschäftsmannes) that the relevant statement is not accurate. For the avoidance of doubt,
such statements shall not be considered violated on grounds that the Company has not conducted an investigation regarding freedom to operate for the Company or its Group Companies. 

 

	4.3	 None of the Guarantees given in this Clause 4 shall be considered as an agreement on the legal and factual
nature (Beschaffenheitsvereinbarung) as defined in section 434 paragraph 1 of the German Civil Code or as a guarantee for certain features of goods sold (Garantie für die Beschaffenheit der Sache) as defined in section 443
paragraph 1 and section 444 of the German Civil Code. 

  

	4.4	 In the event a Guarantee turns out not to be true, accurate or complete in any respect (the Breach of
Guarantee ) the Company shall put the Foundation in such position as it would be in had the Guarantee been true, accurate and complete in any respect (Naturalrestitution). If this is not possible or the Company failed to do so within
four (4) weeks after a respective request by the Foundation, the Company shall compensate the Foundation by way of a compensation capital increase for the Foundations’ damage from the relevant Breach of Guarantee, including, but not
limited to, in any event the Foundations’ pro rata portion (reflecting the Foundations’ fully diluted shareholding in 

  
 8 | 22 

	 	
the Company upon implementation of the Capital Increase) of any damage, loss, expense, reduction in value, or cost of, or incurred by, or necessary to be incurred to remedy the breach by, the
Company as a consequence of the respective Guarantee not being true, accurate and complete by way of the issuance of additional Shares to the Foundation (the Compensating Capital Increase). 

 

	 	(a)	 For the purpose of calculating the compensation owed in Shares for the Foundation’s damages that occur at
the level of the Company, the following formula shall apply: 

 N = (S / (P2 / P1)) - S 

Where: 
 N = Number of Shares to
be issued. 
 S = Number of Shares held by the Foundation. 

P1 = Valuation of the Company for purposes hereof, being 218,748,168 multiplied by the EUR Issuance Price. 

W = EUR amount of the damage, loss, expense, reduction in value, or cost of, or incurred by, or necessary to be incurred to remedy the breach,
the Company as a consequence of the respective Guarantee not being true, accurate and complete. 
 P2 =
P1-W. 
  

	 	(b)	 In the event that the Foundation incurs any damages as a result of a Breach of Guarantee at shareholder level
(i.e. other than damages resulting from the mere fact that the value of the Company be reduced), the Foundation shall receive such number of new Shares to be issued that corresponds to the amount of damages in USD suffered by the Foundation divided
by the USD Issuance Price. 

  

	4.5	 The following limitations shall apply to any claims under Clause 4.4 above (provided that none of these
limitations shall apply in the event of intentional misrepresentation (vorsätzliche Garantieverletzung), malicious intent (Arglist), intentional tort (vorsätzliche
Schädigung) or fraud (Betrug) on the part of the Company: 

  

	 	(a)	 The Company shall be liable for any breach of a Business Guarantee only to the extent the loss arising to the
Foundation with respect to that breach exceeds EUR 500,000 and the total of the losses arising to the Foundation with respect to all of the breaches occurred exceeds EUR 2,000,000; provided, however, that should such total losses exceed
EUR 500,000 and EUR 2,000,000, as applicable, the Foundation shall be entitled to recover the full amount of such losses. 

  

	 	(b)	 The liability of the Company shall be limited such that the aggregate additional Shares to be issued pursuant
to Clause 4.4 do not exceed 100% of the Foundation Shares and do not exceed 75% of the Foundation Shares in connection with Breaches of Business Guarantees. 

  
 9 | 22 

	 	(c)	 The Company shall not be liable pursuant to Clause 4.4 for any breach where the underlying facts, matters or
circumstances forming the basis of a claim (anspruchsbegründende Umstände) were duly (i.e. fully and specifically) disclosed in any of the Exhibits Business Guarantees referred to in Schedule 3 and attached to this Investment
Agreement or, with respect to a breach of the Guarantees as of the Closing Date only, where after the date hereof circumstances have arisen as a result of which a Guarantee is not true, accurate and complete, such circumstances have been notified to
the Foundation in writing by the Company prior to the Closing Date and, provided further, that no such notification shall be deemed to cure any breach of the Guarantees as of the date hereof. 

 

	 	(d)	 Any claims based on a breach of a Title Guarantee shall expire (verjähren) within five
(5) years after the Closing Date. Any claims based on a breach of Business Guarantees shall expire (verjähren) within two (2) years after the Closing Date. 

 

	4.6	 The remedies for Breach of Guarantees set forth in this Investment Agreement shall be the exclusive remedies of
the Foundation for Breach of Guarantees, except for any claims based on intentional misrepresentation (vorsätzliche Garantieverletzung), malicious intent (Arglist), intentional tort
(vorsätzliche Schädigung) or fraud (Betrug) for which neither the limitations set forth in Clause 4.4 nor Clause 4.5 shall apply. All other claims of the Foundation based on, or relating to, any
defects in quality or title (Sach- oder Rechtsmängel), or otherwise in respect of any circumstances relating to the status and condition of the Company and/or its assets, liabilities, financials or business, shall
exclusively be governed by this Investment Agreement. Any further warranty claims (Gewährleistungsansprüche) in connection with defects of the economic, financial or legal situation of the Company or its
assets, whether for damages (Schadenersatz), reduction of price (Minderung), rescission (Rücktritt) or avoidance (Anfechtung) irrespective of its legal basis, whether based on law or contract, including
but not limited to claims based on non-contractual performance (culpa in contrahendo, positive Vertragsverletzung) or claims based on frustration of contract (Störung der
Geschäftsgrundlage) or tort (unerlaubte Handlung) shall be excluded and waived by the Foundation. 

  

	5.	 Withdrawal Right 

The Foundation shall have the right to withdraw its investment in the Company pursuant to the provisions set out in Schedule 4. 

 

	6.	 Shareholders’ Agreement 

Subject to the Amended SHA taking effect, the Foundation hereby declares acceptance of the offer made to it in Clause 24.4 of the Amended SHA
in relation to its accession to the Amended SHA and, as a matter of precaution, agrees to reiterate such declaration in the form prescribed by such provision promptly upon the Conditions having been satisfied. The Parties acknowledge and agree that
the accession agreement brought about by such acceptance of such offer is conditional on the Foundation acquiring the Foundation Shares by virtue of the Registration. 

  
 10 | 22 

	7.	 Final Provisions 

 

	7.1	 Signing process 

  

	 	(a)	 This Investment Agreement is entered into by way of each of the Parties signing on the signature block
designated for it and then transmitting the original or an electronic copy of the signature page with such signature (whether or not included in some or all of the other pages of this document) to the respective other Party. 

 

	 	(b)	 The Company shall make available a copy of this Investment Agreement including the signatures of all Parties
promptly upon it having received the signature pages from the Foundation and itself has signed (also for the purposes of para. (a)). 

  

	7.2	 No Assignment of Rights and Obligations 

Any assignment of rights and/or obligations resulting from or in connection with this Investment Agreement requires the prior written consent
of the other Party hereto except for assignments to an Affiliate of the Foundation. 
  

	7.3	 Confidentiality 

Clause 13 of the Letter Agreement shall apply mutatis mutandis with, as concerns the subject matter of the confidentiality obligations
thereunder, this Agreement being substituted for the Letter Agreement. This confidentiality obligation shall not be affected by the Letter Agreement being terminated or becoming ineffective. 

 

	7.4	 Written Form and Entire Agreement / Amendments 

 

	 	(a)	 Save as contemplated in this Investment Agreement, the Letter Agreement and the Shareholders’ Agreement
and subject to the succeeding sentence, this Investment Agreement constitutes the entire agreement between the Parties in relation to its subject matter and supersedes all previous agreements and understandings between the Parties in relation
thereto. This shall not apply to the arrangements disclosed in Annex 31.2 to the Shareholders’ Agreement. 

  

	 	(b)	 Amendments to this Investment Agreement, including this written form requirement itself, must be made in
writing in order to become enforceable and effective unless mandatory law requires a stricter form. 

  

	 	(c)	 Wherever this Investment Agreement requires the written form or a declaration or other act to be made in
writing, the submission by telefax or email of a copy of the executed original shall suffice. Any notice required or contemplated to be given pursuant to or for purposes of this Investment Agreement shall be made in text form (Textform)
(including by email), subject to any requirement herein for such act to be made in the written form or in writing. 

  

	7.5	 Costs 

All costs incurred by the Parties in connection with this Investment Agreement and the measures provided for in it shall be borne by the Party
incurring such costs, except as expressly provided otherwise in this Investment Agreement or the Shareholders Agreement. 

  
 11 | 22 

	7.6	 Notices 

Clause 22 of the Shareholders’ Agreement as to addresses and certain authorities shall apply mutatis mutandis. This provision shall
not be affected by the Shareholders’ Agreement being terminated or becoming ineffective. 
  

	7.7	 Severability 

In the event any provision hereof is or shall become invalid or unenforceable, the validity of the other provisions shall remain unaffected. In
lieu of the invalid or unenforceable provision, such valid and enforceable provision shall be deemed to be agreed upon which most closely corresponds to the intended economic purpose of the invalid or unenforceable provision. Without prejudice to
the preceding sentence, the Parties shall expressly agree on such valid and enforceable provision. 
  

	7.8	 Choice of Law and Resolution of Disputes 

 

	 	(a)	 This Investment Agreement shall be governed by the laws of the Federal Republic of Germany without recourse to
the German conflicts of law rules. 

  

	 	(b)	 All disputes arising in connection with this Investment Agreement or its validity shall be finally settled in
accordance with the Arbitration Rules of the German Institution of Arbitration (Deutsche Institution für Schiedsgerichtsbarkeit (DIS) e.V.) without recourse to the ordinary courts of law. The place of arbitration is Frankfurt, Germany.
The number of arbitrators is three. The language of the arbitral proceedings is English. 

  

					
	 BioNTech SE
 Signatures:
	 		 	 Bill & Melinda Gates Foundation

Signatures:

			
	[***]	 		 	[***]
	Name(s) of individual(s) signing:	 		 	Name(s) of individual(s) signing:
			
	[***]	 		 	[***]
	Function(s) of individual(s) signing:	 		 	Function(s) of individual(s) signing:
			
	[***]	 		 	[***]

  
 12 | 22 

 Schedule 1 

Corporate action in relation to Withdrawal Right 
  

	1.	 Authorization by the Company’s shareholders’ meeting to purchase treasury shares.

  

	2.	 Approval of supervisory board that shares held by the Foundation or its Affiliates can be transferred in case
the Withdrawal Right as defined in Clause 1.1 of Schedule 4 is exercised. 

  
 13 | 22 

 Schedule 2 

Amended SHA 

  
 14 | 22 

 Schedule 3 

Business Guarantees 
  

	1.	 The financial statements of the Company and of the Group each as of 31 December 2018 as presented to the
Investor have been prepared in accordance with and fairly present the financial condition and operating results of the Company and the Group, respectively, as of such date according to the German Commercial Code (Handelsgesetzbuch, HGB).

  

	2.	 Each Group Company has been granted all governmental permits necessary for the conduct of its business as now
being conducted by it, the lack of which could materially and adversely affect the business, properties, prospects, or financial condition of the Company, and none of such permits has been revoked or can be revoked as a result of the relevant Group
Company not having complied with conditions to which the relevant permit is subject. 

  

	3.	 No Group Company is in material violation of any applicable statute, law or regulation relating to the
environment or occupational health and safety and no material expenditures are or will be required in order to comply with any such existing statute, law or regulation. 

 

	4.	 To the Company’s Knowledge each Group Company owns, or is licensed to use, all patents, patent
applications, design and utility models, trademarks, service marks, trade names, copyright, internet domain names, trade secrets, information, proprietary rights and processes and other intellectual property rights, including, without limitation,
all applications therefore necessary for its research, development and similar activities as conducted by that Group Company without any conflict with or infringement of the rights of others. 

 

	5.	 To the Company’s Knowledge, there is no violation or infringement by a third party of any of the
Company’s rights in its intellectual property. 

  

	6.	 Except as set out in [***] no action, suit, proceeding or investigation is pending or, to the
Best Knowledge of the Company, currently threatened against any Group Company that might result, either individually or in the aggregate, in any adverse changes in the assets, operations, prospects or financial condition of that Group Company.

  

	7.	 No Group Company is a party or subject to the provisions of any order, writ, injunction, judgment, settlement
or decree of any court or government agency or instrumentality. 

  

	8.	 Within the three years prior to the date hereof, other than to another Group Company, none of the Group
Companies has disposed of or licensed any of its assets or its intellectual property rights to any party which at the relevant time was or as of the date hereof is a direct or indirect shareholder of the Company or a member of the management or
supervisory board or any affiliate of such shareholder or management or supervisory board member. 

  

	9.	 Except as set out in [***] the Group Companies have always complied with the relevant provisions
with respect to wages, Taxes, pensions and social security contributions and have always paid Taxes and duties when due, and in particular have properly withheld and paid the employees contributions. Taxes means all direct or indirect
federal, state, local or foreign taxes, assessments, stamp duties, real estate transfer taxes, levies or 

  
 15 | 22 

	 	
public law charges of any kind, including without limitation, social security contributions, together with any interest and any penalties, additions to tax or additional amounts imposed by any
governmental authority, domestic or foreign. 

  

	10.	 None of the Group Companies, nor to the Best Knowledge of the Company, any director, officer, agent, employee,
or person acting on behalf of any of the Group Companies is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (OFAC), and the Company will not directly or
indirectly use the proceeds of the sale of the Shares, or lend, contribute or otherwise make available such proceeds to any Group Company, joint venture partner or other person or entity, towards any sales or operations in Cuba, Iran, Syria, Sudan,
Myanmar or any other country sanctioned by OFAC or for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. 

 

	11.	 The operation of each of the Group Companies are and have been conducted at all times in compliance with the
anti-money laundering statues of applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable governmental agency (collectively, the
“Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving any of the Group Companies with respect to the Money Laundering Laws is
pending, or to the Best Knowledge of the Company, threatened. 

  

	12.	 None of the Group Companies nor, to the Best Knowledge of the Company, any person authorized to act on behalf
of any of the Group Companies, directly or indirectly, (i) has used any funds or will use such funds or any proceeds from the sale of the Shares for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or
domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any
contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as
amended and the rules and regulations thereunder. 

  
 16 | 22 

 Schedule 4 

Withdrawal Right 
  

	1.	 Condition Precedent for Withdrawal Right and Definitions 

 

	1.1	 Subject to the issuance of the Foundation Shares and the payment of the USD Issuance Price, the Foundation
shall have the rights as set out in Clauses 2 through 4 of this Schedule (the Withdrawal Right). 

  

	1.2	 The following definitions apply: 

 

	 	(a)	 Available Liquidity means the liquidity which the Company can apply to making payments under this
Withdrawal Right without triggering an insolvency event pursuant to section 17 German Insolvency Code (Insolvenzordnung, InsO). 

  

	 	(b)	 Current Foundation Shares means all of the Foundation Shares collectively held by the Foundation
and its Affiliates at the relevant time. 

  

	 	(c)	 Exercise Date means the date of a Put-Option Exercise.
For the avoidance of doubt there may be more than one Exercise Date. 

  

	 	(d)	 FMV Purchase Price shall mean (i) if the Shares or rights or certificates representing the
Shares are freely tradable, the closing price per Share or per right or certificate (collectively the ADS) on the last day preceding the Exercise Date on which the Shares or rights or certificates were traded on the relevant exchange
or trading facility or (ii) if the Shares are not freely tradable, the then current fair market value of the Company divided by the number of Shares outstanding as determined by a mutually agreed upon (such agreement not to be unreasonably
withheld) independent third-party appraiser. 

  

	 	(e)	 Minimum Purchase Price shall mean the [***]. 

 

	 	(f)	 Unrestricted Reserves shall mean the unrestricted reserves of the Company in accordance with
section 71 para. 2 sentence 2 German Stock Corporation Act (Aktiengesetz, AktG). 

  

	2.	 Put-Option 

 

	2.1	 The Company irrevocably grants to the Foundation and its Affiliates (echter Vertrag zu Gunsten Dritter)
the option to sell and transfer the Foundation Shares to the Company pursuant to the terms set out in this Clause 2 (the Put-Option) provided that the
Put-Option can only be exercised for all of the Current Foundation Shares, subject to Clause 2.4 below. 

  

	2.2	 Irrespective of whether or not an Option Readiness Notice (as defined in Clause 2.8) has been given, the Put-Option can be exercised at any time following the occurrence of a Charitability Default as defined in the Letter Agreement (the Put-Option Exercise) by the
Foundation or its Affiliates giving the Company an exercise notice stating (i) that the Foundation or the relevant Affiliate is exercising the Put-Option; (ii) the date on which the exercise notice
is given; and (iii) the number of Foundation Shares in respect of which the Put-Option is exercised (the Put-Option Shares, subject to Clause 2.4
below). 

  
 17 | 22 

	2.3	 The price for each Foundation Share shall be the Minimum Purchase Price (with the Minimum Purchase Price
multiplied by the Put-Option Shares being the Purchase Price Put Option). 

  

	2.4	 In the event that the Purchase Price Put Option (save for the effects of this Clause 2.4) exceeds the amount of
Unrestricted Reserves or the Available Liquidity as of the relevant Exercise Date, the number of the Put-Option Shares shall be reduced such that the Purchase Price Put Option as then results from Clause 2.3
is equal to or lower than (but comes as close as possible to) each of the amount of Unrestricted Reserves and the Available Liquidity as of the relevant Exercise Date. In the event the number of Put-Option
Shares is reduced pursuant to this Clause 2.4, the Put-Option and the other provisions of this Schedule 4 will continue to apply with respect to all remaining Foundation Shares. 

 

	2.5	 The Purchase Price Put Option shall be due and payable net of costs within 90 Business Days after the Put-Option Exercise. 

  

	2.6	 The Foundation or its Affiliate, as the case may be, shall enter into a transfer and assignment agreement
pursuant to which the Put-Option Shares will be assigned to the Company subject to receipt of the Purchase Price Put Option. 

 

	2.7	 The Foundation Shares sold pursuant to the Put-Option shall be sold
free of encumbrances and any rights of third parties. 

  

	2.8	 At each time when there are Unrestricted Reserves and Available Liquidity such that in the event of a Put-Option Exercise the number of the Put-Option Shares as determined pursuant to Clause 2.2 and 2.4 would be at least [***]% of the Foundation Shares or all of the Current
Foundation Shares the Company shall notify the Foundation in writing of the amount of Unrestricted Reserves and, in case the Available Liquidity is lower than the amount of the Unrestricted Reserves, also of the amount of the Available Liquidity
(Option Readiness Notice), following which the Foundation may determine in its full discretion whether it wishes to exercise the Put-Option. In any event, following a Charitability Default, as
long as the Foundation holds any of the Foundation Shares, the Company shall notify the Foundation at least by the fifteenth business day of each month following the end of a calendar quarter of the amount of the Unrestricted Reserves and the
Available Liquidity, provided the amount of the latter is lower than the amount of Unrestricted Reserves. 

  

	3.	 Sale to Third Party 

 

	3.1	 As long as the Foundation Shares have not been transferred to the Company under the Put-Option and in the event of a Charitability Default 

  

	 	(a)	 at the request of the Foundation, the Company shall, without undue delay and using reasonable best efforts,
locate a third-party that will purchase all Foundation Shares held by the Foundation or its Affiliates for no less than the Minimum Purchase Price per Foundation Share (such request the Sale Request) (for clarity the FMV Purchase Price
shall be determined as of the date of conclusion of a binding purchase agreement in that respect); and 

  

	 	(b)	 the Foundation is entitled to sell all Foundation Shares held by the Foundation or its Affiliates at the time
(i) to a third-party (one or more) that is not a Direct 

  
 18 | 22 

	 	
Competitor (as defined in the Letter Agreement) where such sale is prior to an IPO or (ii) to a third-party (one or more) of its choosing where such sale is following an IPO, in each case
without any restrictions to such transfer of Foundation Shares attached to it with the exception of, if applicable, accession to a shareholders’ agreement to which the Foundation or its successor or Affiliates is a party and the Company will
take all measures to the extent such measures are not unreasonable, to facilitate such sale to a third party, including, but not limited to, following an IPO (as defined in the Shareholders Agreement), all measures required for a sale of the
Shares held by the Foundation or its Affiliates over the relevant stock exchange, e.g. in case of a listing of such Foundation Shares at a US stock exchange, registering such sale of the Foundation Shares on an effective registration statement
unless such sale can be effected to the public under Rule 144 of the Securities Act without volume limitations. The Foundation agrees that if it sells the Foundation Shares (or any ADS that is issued to the Foundation in exchange for the Foundation
Shares (a Foundation ADS)) pursuant to this Section 3.1(b) following an IPO, it will use its reasonable best efforts to liquidate the Foundation Shares or Foundation ADSs in a manner that will avoid causing a material decrease in
the Company’s stock or ADS trading price, as applicable, which may include seeking a block trade with a private purchaser or spreading the sales out over time; provided that nothing in this provision will limit the Foundation’s right to
liquidate the Foundation Shares or Foundation ADSs in a manner the Foundation determines is necessary to comply with applicable law, including applicable prudent investor standards. To the extent permissible under applicable securities and other
laws, the Foundation shall promptly inform the Company when it has mandated a securities broker in relation to a sale of the Foundation Shares or the Foundation ADSs or if the Foundation has executed a block trade. 

 

	4.	 Report on Holdings for Company’s Accounting Purposes 

By the fifteenth day of each month following the end of any calendar quarter, if there has been any change in the number of Foundation Shares
or Foundation ADSs held by the Foundation during such calendar quarter, the Foundation shall disclose to the Company the amount of any Foundation Shares or Foundation ADSs being held by the Foundation or its Affiliates as of the last calendar day of
such calendar quarter. 
  

	5.	 Specific Obligations to ensure the Withdrawal Right 

 

	5.1	 The Parties agree that the purpose of the Withdrawal Right is to ensure the Foundation’s ability,
following the occurrence of a Charitability Default, to divest the Foundation Shares held by the Foundation or its Affiliates at no less than the Minimum Purchase Price per Foundation Share. 

 

	5.2	 If, for whatever reason, legal or otherwise, (i) after the Foundation has exercised its Put-Option, the Company is unable to redeem all of the Current Foundation Shares for legal or other reasons, e.g. the Company not having sufficient Unrestricted Reserves or (ii) the Company is unable to
locate a third party to acquire the Foundation Shares pursuant to Clause 3.1(a) of this Schedule, upon request of the Foundation, the Company shall acquire as many of the Current Foundation Shares for the Minimum

  
 19 | 22 

	 	
Purchase Price per Foundation Share (for clarity the FMV Purchase Price shall be determined as of the date of conclusion of a binding purchase agreement in that respect) as are legally
permissible and can be acquired out of Available Liquidity and continuously use its best efforts to effect the purchase of the remaining Foundation Shares for the Minimum Purchase Price per Foundation Share, consistent with applicable law, until
such time as the Foundation and its Affiliates no longer hold any Shares. 

  

	5.3	 If the Foundation sells its Foundation Shares pursuant to Clause 3.1(b) of this Schedule and prior to selling
its Foundation Shares (i) the Foundation has issued a Sale Request and (ii) two months have passed since such Sale Request without the Company having presented a suitable third-party purchaser, to the extent permitted by law, the Company
will compensate the Foundation for any difference between the amount received by the Foundation as a result of such sale and the amount of the Minimum Purchase Price times the Foundation Shares sold (for clarity the FMV Purchase Price shall be
determined as of the date of conclusion of a binding purchase agreement in that respect) (such difference the Shortfall Amount). The Company shall have the right to defer the payment of the Shortfall Amount into [***]. The Company will
issue the Foundation a promissory note (the Shortfall Amount Note) for the amount due which will bear interest at a rate of [***]% per annum and will immediately become due and payable in full in the event of an Acquisition Transaction
(as defined in the Letter Agreement). 

  

	5.4	 To the extent permitted by law and subject to Clause 5.5, for as long as the Foundation holds Shares or there
is an obligation outstanding from the Company to compensate the Foundation for a Shortfall Amount, 

  

	 	(a)	 the Company shall procure that no dividends are paid on any of its share capital, no Shares of any other
Shareholder of the Company are redeemed (other than repurchases at cost of Shares of the share capital from employees, officers, directors, consultants or other persons performing services for the Company or any Affiliate pursuant to agreements
under which the Company has the option to repurchase such Shares upon the occurrence of the termination of employment or service) and no other distribution to any other Shareholder of the Company in respect of the share capital held by such
Shareholders is being made (any such transaction a Distribution), and 

  

	 	(b)	 annual profits shall, to the extent permitted by law, be contributed to the Unrestricted Reserves up to the USD
Issuance Price times the Current Foundation Shares (the Aggregate USD Issuance Price and such obligation the Build-up Obligation), provided however that if at any time following a
Charitability Default for any reason either the Company has not repurchased any or all of the Foundation Shares (under the Put-Option or pursuant to Clause 5.2) or there is an obligation outstanding from the
Company to compensate the Foundation for a Shortfall Amount (the time during which either such case exists, the Default Period) the Build-up Obligation shall require the Company to contribute
annual profits to the Unrestricted Reserves up to the amount equal to the Minimum Purchase Price times the Current Foundation Shares (the Aggregate Minimum Purchase Price) rather than the Aggregate USD Issuance Price.

  

	5.5	 Any Distribution shall be permitted and the Build-up Obligation does
not apply solely 

  
 20 | 22 

	 	(a)	 prior to a Default Period: to the extent the Unrestricted Reserves of the Company as of the annual financial
statements reference date exceed the Aggregate USD Issuance Price, 

  

	 	(b)	 during a Default Period: to the extent the Unrestricted Reserves of the Company as of the annual financial
statements reference date exceed the Aggregate Minimum Purchase Price, but only at each time after the Company has given an Option Readiness Notice and the Foundation has not after such Option Readiness Notice exercised the Put-Option within one month after receiving such Option Readiness Notice and only for as long as the Foundation does not after such Option Readiness Notice exercise the
Put-Option and 

  

	 	(c)	 during a Default Period in the event that the only remaining obligation of the Company with respect to the
Withdrawal Right is payment of any remaining amounts due under the Shortfall Amount Note and the Company is not in default on such note. 

  

	5.6	 Notwithstanding anything in this Schedule 4, the Company shall use best endeavors to cause such arrangements to
be made as is required to effect the Withdrawal Right to the largest extent permitted by law. In the event any such arrangements shall become invalid or unenforceable, the Company shall effectuate any measures required to effect the Withdrawal
Right. Such measures inter alia include the execution of new put-option agreements, obtaining the supervisory board’s approval for the transfer of the Foundation Shares or obtaining a new
authorization for purchasing treasury shares pursuant to section 71 para. 1 no. 8 German Stock Corporation Act (Aktiengesetz, AktG) from the shareholders’ meeting of the Company. 

 

	6.	 Costs 

The Company shall pay all fees and expenses incident to the performance of or compliance with this Schedule 4 by the Company. 

 

	7.	 No Effect on Letter Agreement 

For the avoidance of doubt it is understood by the Parties that the validity of the Letter Agreement and any project agreed on in connection
with the Global Access Commitments (as defined in the Global Access Commitments) shall continue regardless of a sale of the Foundation Shares pursuant to this Schedule 4 and the Foundation shall continue to be entitled to enforce its rights under
the Letter Agreement and in relation to any agreed projects. 

  
 21 | 22 

 PAGE INTENTIONALLY LEFT BLANK 

  
 22 | 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]